-+ 0.00%
-+ 0.00%
-+ 0.00%

Reyon Pharmaceutical to Repurchase KRW 950 Million in Debt Before Maturity

PUBT·10/26/2026 08:21:13
Reyon Pharmaceutical to Repurchase KRW 950 Million in Debt Before Maturity
  • Reyon Pharmaceutical will repurchase KRW 950 million of third-series convertible bonds before maturity on Oct. 26, 2026.
  • The purchase price totals KRW 1.05 billion, including principal and interest, funded with internal cash.
  • Outstanding principal will fall to KRW 83.95 billion; the bonds mature on Oct. 25, 2029.
  • The board will determine the repurchased bonds' subsequent treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reyon Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261026000297), on October 26, 2026, and is solely responsible for the information contained therein.